Literature DB >> 24089328

A Mendelian predisposition to B-cell lymphoma caused by IL-10R deficiency.

Bénédicte Neven1, Emilie Mamessier, Julie Bruneau, Sophie Kaltenbach, Daniel Kotlarz, Felipe Suarez, Julien Masliah-Planchon, Katy Billot, Danielle Canioni, Pierre Frange, Isabelle Radford-Weiss, Vahid Asnafi, Dhaarini Murugan, Christine Bole, Patrick Nitschke, Olivier Goulet, Jean-Laurent Casanova, Stéphane Blanche, Capucine Picard, Olivier Hermine, Frederic Rieux-Laucat, Nicole Brousse, Frederic Davi, Véronique Baud, Christoph Klein, Bertrand Nadel, Frank Ruemmele, Alain Fischer.   

Abstract

Monogenic interleukin-10 (IL-10) and IL-10 receptor (IL-10R) deficiencies cause very early onset severe inflammatory bowel disease. Here, we report that 5 patients with an IL-10R1 (n = 1) or IL-10R2 (n = 4) deficiency developed B-cell non-Hodgkin lymphoma between the ages of 5 and 6 years (which was recurrent in 1 patient). These lymphomas had some of the characteristics of diffuse large B-cell lymphomas and contained monoclonal, Epstein-Barr virus-negative germinal center B cells. The tumors displayed a remarkably homogeneous signature, with original activation of the nuclear factor κB pathway and a decrease in intratumor T-cell infiltration. Hence, IL-10R deficiency is associated with a high risk of developing B-cell lymphoma. Our results revealed an unexpected role of the IL-10R pathway in lymphomagenesis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24089328     DOI: 10.1182/blood-2013-06-508267

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  48 in total

Review 1.  Microenvironment abnormalities and lymphomagenesis: Immunological aspects.

Authors:  Joseph G Taylor; John G Gribben
Journal:  Semin Cancer Biol       Date:  2015-07-29       Impact factor: 15.707

Review 2.  The Treatment of Inflammatory Bowel Disease in Patients with Selected Primary Immunodeficiencies.

Authors:  Dror S Shouval; Matthew Kowalik; Scott B Snapper
Journal:  J Clin Immunol       Date:  2018-06-29       Impact factor: 8.317

3.  The Unique Disease Course of Children with Very Early onset-Inflammatory Bowel Disease.

Authors:  Judith R Kelsen; Maire A Conrad; Noor Dawany; Trusha Patel; Rawan Shraim; Audrey Merz; Kelly Maurer; Kathleen E Sullivan; Marcella Devoto
Journal:  Inflamm Bowel Dis       Date:  2020-05-12       Impact factor: 5.325

4.  T-cell Expression of IL10 Is Essential for Tumor Immune Surveillance in the Small Intestine.

Authors:  Kristen L Dennis; Abdulrahman Saadalla; Nichole R Blatner; Shuya Wang; Vysak Venkateswaran; Fotini Gounari; Hilde Cheroutre; Casey T Weaver; Axel Roers; Nejat K Egilmez; Khashayarsha Khazaie
Journal:  Cancer Immunol Res       Date:  2015-04-08       Impact factor: 11.151

Review 5.  The role of monogenic disease in children with very early onset inflammatory bowel disease.

Authors:  Judith R Kelsen; Robert N Baldassano
Journal:  Curr Opin Pediatr       Date:  2017-10       Impact factor: 2.856

Review 6.  Genomic and Immunologic Drivers of Very Early-Onset Inflammatory Bowel Disease.

Authors:  Maire A Conrad; Judith R Kelsen
Journal:  Pediatr Dev Pathol       Date:  2019-03-06

7.  PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8+ T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients.

Authors:  Aung Naing; Jeffrey R Infante; Kyriakos P Papadopoulos; Ivan H Chan; Cong Shen; Navneet P Ratti; Bianca Rojo; Karen A Autio; Deborah J Wong; Manish R Patel; Patrick A Ott; Gerald S Falchook; Shubham Pant; Annie Hung; Kara L Pekarek; Victoria Wu; Matthew Adamow; Scott McCauley; John B Mumm; Phillip Wong; Peter Van Vlasselaer; Joseph Leveque; Nizar M Tannir; Martin Oft
Journal:  Cancer Cell       Date:  2018-11-12       Impact factor: 31.743

Review 8.  Very early-onset inflammatory bowel disease: gaining insight through focused discovery.

Authors:  Christopher J Moran; Christoph Klein; Aleixo M Muise; Scott B Snapper
Journal:  Inflamm Bowel Dis       Date:  2015-05       Impact factor: 5.325

9.  Safety, Antitumor Activity, and Immune Activation of Pegylated Recombinant Human Interleukin-10 (AM0010) in Patients With Advanced Solid Tumors.

Authors:  Aung Naing; Kyriakos P Papadopoulos; Karen A Autio; Patrick A Ott; Manish R Patel; Deborah J Wong; Gerald S Falchook; Shubham Pant; Melinda Whiteside; Drew R Rasco; John B Mumm; Ivan H Chan; Johanna C Bendell; Todd M Bauer; Rivka R Colen; David S Hong; Peter Van Vlasselaer; Nizar M Tannir; Martin Oft; Jeffrey R Infante
Journal:  J Clin Oncol       Date:  2016-10-10       Impact factor: 44.544

10.  Cross-talk among myeloid-derived suppressor cells, macrophages, and tumor cells impacts the inflammatory milieu of solid tumors.

Authors:  Daniel W Beury; Katherine H Parker; Maeva Nyandjo; Pratima Sinha; Kayla A Carter; Suzanne Ostrand-Rosenberg
Journal:  J Leukoc Biol       Date:  2014-08-28       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.